ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy For Lymphoma
Favrille, Inc. (Nasdaq:
FVRL), a biopharmaceutical company developing patient-specific, active
immunotherapies for the treatment of cancer, announced results from a new
study showing enhanced activity from insect-cell derived idiotype (Id)
proteins, a key component in the Company's Id/KLH immunotherapy product
candidate FavId(R) for B-cell non-Hodgkin's lymphoma (NHL), compared to Id
proteins produced using mammalian cells. The data were reported today at
the American Association for Cancer Research (AACR) Annual Meeting in Los
Angeles.
"Our data show that production of recombinant Id proteins via an insect
cell system results in a structurally different antigen with improved
immunogenicity compared to mammalian cell-derived Id proteins," said
co-author John Timmerman, M.D., and Assistant Professor of Medicine,
Division of Hematology and Oncology at the University of California, Los
Angeles, where much of the study was performed. "This in turn may lead to
improved activity of the final Id-KLH immunotherapy for lymphoma."
A copy of the poster presented by Dr. Timmerman, entitled "Enhanced
Immunostimulation by a Therapeutic Lymphoma Idiotype Vaccine Produced in
Insect Cells Involves Mannose Receptor Targeting to Antigen Presenting
Cells," is now available on the Investor Relations section of Favrille's
web site at http://www.favrille.com.
"This study demonstrates that Id protein produced by insect cell lines
possesses an enhanced ability to interact with dendritic cells compared to
the same protein produced in mammalian cells, which in turn stimulates an
enhanced immune response," said Daniel Gold, Ph.D., Favrille's Chief
Scientific Officer. "These data help support our belief that the use of
insect cells provides not only the most efficient method for producing
Id/KLH immunotherapies, but also the added advantage of making them
potentially more active as well."
About FavId
FavId is a patient-specific, Id/KLH active immunotherapy for the
treatment of B-cell NHL. Favrille completed enrollment in its pivotal Phase
3 clinical trial of FavId following Rituxan(R) induction therapy in
patients with follicular B-cell NHL in January 2006. Analysis of the
primary endpoint, time to disease progression, is event driven and
currently projected to occur during the fourth quarter of 2007. The Company
has a Special Protocol Assessment from the U.S. Food and Drug
Administration (FDA) for its Phase 3 trial, and has also received Fast
Track designation for FavId from the FDA.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the
development and commercialization of targeted immunotherapies for the
treatment of cancer and other diseases of the immune system. The Company's
lead product candidate, FavId, is based upon unique genetic information
extracted from a patient's tumor. FavId is currently under investigation in
a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL
and Phase 2 clinical trials in other B-cell NHL indications. The Company is
developing additional applications based on its immunotherapy expertise and
proprietary cost- effective manufacturing technology, including a second
product candidate, FAV- 201, for the treatment of cutaneous T-cell
lymphoma.
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to Favrille's product candidates,
proprietary technologies and research programs. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause Favrille's actual results to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. These factors include, but are not limited to,
risks and uncertainties related to progress and timing of clinical trials
for FavId, including difficulties or delays in development, testing,
manufacturing and marketing FavId or Favrille's other product candidates;
Favrille's ability to obtain marketing approval for FavId or Favrille's
other product candidates and the timing of any such approvals; Favrille's
ability to manufacture sufficient quantities of FavId for use in clinical
trials and, if FavId receives marketing approval, for commercialization;
risks associated with achieving projected operating metrics and financial
performance or the anticipated number of patients using FavId; potential
delays in patient enrollment; Favrille's ability to obtain additional
financing to support its operations; and additional risks discussed in
Favrille's filings with the Securities and Exchange Commission. In
addition, conclusions regarding the safety and efficacy of Favrille's
product candidates cannot be made until the results of future clinical
trials of longer duration in more patients are known. All forward-looking
statements are qualified in their entirety by this cautionary statement.
Favrille is providing this information as of the date of this release and,
except as required by law, does not undertake any obligation to update any
forward- looking statements contained in this release as a result of new
information, future events or otherwise.
Favrille, Inc.
http://www.favrille.com
View drug information on Rituxan.
Favrille anunþã rezultate de la studiu care sã arate consolidatã de activitate de la insecte de celule derivate de imunoterapie pentru limfom - Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy For Lymphoma - articole medicale engleza - startsanatate